80775-52-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,5-dibromothiophen-2-yl)ethanone serves as a crucial intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure contributes to the development of new drugs with potential therapeutic applications.
Used in Dye Industry:
In the dye industry, 1-(3,5-dibromothiophen-2-yl)ethanone is utilized as an intermediate for the production of organic dyes. Its chemical properties enable the creation of dyes with specific color characteristics and stability, catering to various industrial needs.
As a hazardous substance, 1-(3,5-dibromothiophen-2-yl)ethanone requires proper handling and storage to prevent exposure and minimize potential health and environmental hazards. Adhering to safety guidelines and precautions is essential when working with this chemical compound.

Upstream product

• 3140-92-9 2,4-dibromothiophene 
• 75-36-5 acetyl chloride 
• 3141-24-0 2,3,5-tribromothiophene 
• 3141-27-3 2,5-dibromothiophen 
• 78191-00-1 N-Methoxy-N-methylacetamide 

Relevant academic research and scientific papers

Light-Activated Sensitive Probes for Amine Detection

Our new, simple, and accurate colorimetric method is based on diarylethenes (DAEs) for the rapid detection of a wide range of primary and secondary amines. The probes consist of aldehyde- or ketone-substituted diarylethenes, which undergo an amine-induced decoloration reaction, selectively to give the ring-closed isomer. Thus, these probes can be activated at the desired moment by light irradiation, with a sensitivity that allows the detection of amines at concentrations as low as 10?6m in solution. In addition, the practical immobilization of DAEs on paper makes it possible to detect biogenic amines, such as cadaverine, in the gas phase above a threshold of 12 ppbv within 30 seconds.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

A convenient and efficient preparation of 2-acetyl-4,5-difluorothiophene

A convenient, five-step preparation of 2-acetyl-4,5-difluorothiophene from 2,3-dibromothiophene is described. Copyright Taylor & Francis Group, LLC.

INHIBITORS OF AKT ACTIVITY

Invented are novel pyridine compounds, the use of such compounds as inhibitors of PKB/AKT kinase activity and in the treatment of cancer and arthritis.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.

Bromothiophene Reactions. I. Friedel-Crafts Acylation

Friedel-Crafts acylation of 2,5-dibromo- and 2,3,5-tribromothiophenes with different acyl chlorides and anhydrous aluminium trichloride has been studied.The reaction afforded a mixture of acyl derivatives and tetrabromothiophene.The results obtained suggest a mechanism which involves the formation of bromine cations in the reaction medium.Several products obtained in this reaction are described.